Day: July 15, 2025

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, is pleased to announce the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study (ClinicalTrials.gov as NCT06072612) in metastatic breast cancer. BriaCell’s Phase 3 study now has 69 active clinical sites across 15 states, including Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive...

FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetes FDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for both accelerated approval and for full approval Nearly half of the patients required for the accelerated approval analysis using eGFR slope have been enrolled Topline data to support an application for accelerated approval is anticipated in Q2 2027WINSTON-SALEM, N.C., July 15, 2025 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced confirmation of alignment with the U.S. Food and Drug Administration (FDA) on the accelerated approval pathway for rilparencel....

Vancouver, BC, Canada, July 15, 2025 (GLOBE NEWSWIRE) — WestKam Gold Corp. (TSXV:WKG) (the “Company” or “WestKam”), further to its news release of July 2, 2025 (the “MCTO Announcement”), provides an update with respect to the management cease trade order (the “MCTO”) dated July 2, 2025, issued by the British Columbia Securities Commission (the “BCSC”) in connection with the delay by the Company in filing its interim financial statements, the related management’s discussion and analysis and the related officer certifications for the six month period ended April 30, 2025 (collectively, the “Interim Filings”), before the filing deadline of June 30, 2025 (the “Filing Deadline”) as required under applicable Canadian securities laws. The Company was unable to file the Interim Filings prior to the required deadline as its CFO, Pam Saulnier,...

Presentation by trial principal investigator at the 2025 SNO/ASCO CNS Metastases Conference Plus will also host an educational symposium with leading experts titled, “Reimagining Your Approach to Leptomeningeal Metastases” HOUSTON, July 15, 2025 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announces the oral presentation of its ReSPECT-LM clinical trial results and a sponsored educational symposium, at the upcoming SNO/ASCO CNS Metastases Conference on August 14-16, 2025, at the Baltimore Waterfront Marriott Hotel in Baltimore, MD.   “Previously presented data from ReSPECT-LM was highly encouraging in both the safety profile and response signal...

Steven Pfanstiel, a seasoned financial executive with extensive medical technology and pharmaceutical experience, replaces Steve Furlong as Chief Financial Officer following previously announced succession process Neuronetics reiterates guidance for second quarter and full year 2025 MALVERN, Pa., July 15, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that Steven Pfanstiel has been appointed as the company’s new Chief Financial Officer, effective July 15, 2025. Mr. Pfanstiel replaces Steve Furlong, who announced his intention to retire on March 31, 2026. Mr. Furlong will...

JACKSONVILLE, Fla., July 15, 2025 (GLOBE NEWSWIRE) — Landstar System, Inc. (NASDAQ:LSTR), announced today it will release its 2025 second quarter results after the market closes on Tuesday, July 29, 2025, and will then hold its quarterly conference call with analysts and investors at 4:30 p.m. ET that evening to discuss the second quarter results. To access the webcast, visit investor.landstar.com; click on “Webcasts”; and then “Landstar’s Second Quarter 2025 Earnings Release Conference Call.” For those unable to participate in the live call, or for those who do not have access to the Internet, the call will be available on telephone replay for 48 hours. The telephone replay number for the U.S. and Canada is (800) 819-5743 and for international calls is (203) 369-3828. About Landstar: Landstar System,...

The Trial Exceeded Target Overall Response Rate (ORR) of 20%, with 44% Response Rate Among Patients with Acute Myeloid Leukemia-Myelodysplasia-Related Changes (AML MR) Treated at Optimal Dose of 30 mg Twice a Week (BIW) and 50% in AML MR with Myelomonocytic/Myelomonoblastic (M4/M5) Subtype Median Overall Survival (mOS) of 8.9 Months in Patients with AML MR and 8.8 mOS in Relapsed or Refractory to Venetoclax-Based Regimens at 30 mg BIW Dose Level Surpasses the Historical Benchmark of 2.4 Months FDA Recommends Advancement towards a Trial Including Newly Diagnosed First-Line AML Patient Cohorts That May Support a New Drug Application; Trial Preparation Underway with Enrollment Expected to Begin by Q1 2026NEW YORK, July 15, 2025 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage...

“Company Plans to Explore Cryptocurrency Treasury Model” WOODS CROSS, Utah, July 15, 2025 (GLOBE NEWSWIRE) — Sky Quarry Inc. (NASDAQ: SKYQ) (“Sky Quarry” or “the Company”), an integrated energy company focused on sustainable resource recovery, today announced a strategic initiative to establish a digital asset treasury as part of its broader capital allocation strategy. Recognizing the growing institutional acceptance of digital assets in public markets, Sky Quarry is actively exploring how a targeted digital asset strategy can complement and enhance its existing business model. The Company believes this approach will not only strengthen its balance sheet but also unlock meaningful value for shareholders. The initiative aims to improve transparency, boost capital efficiency, and build long-term confidence in the Company’s financial...

– Alignment gained on Phase 2 inclusion/exclusion criteria, primary and secondary endpoints, and study design, including sample size and dosing regimen – Company expects to begin enrolling patients in Phase 2 in 2H 2025 SAN DIEGO and SUZHOU, China, July 15, 2025 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced outcomes from its Type B meeting with the United States Food and Drug Administration (FDA). Adagene has received written feedback from the FDA on its clinical development plan to evaluate muzastotug (ADG126) in combination with Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab: 200 mg, Q3W) in patients with microsatellite stable colorectal...

AUSTIN, Texas, July 15, 2025 (GLOBE NEWSWIRE) — Accelsius, a leader in advanced data center cooling solutions, announced that its proprietary NeuCool™ IR80 system will be deployed in Q3 2025 at Equinix’s Co-Innovation Facility (CIF) in the DC15 International Business Exchange™ (IBX®) data center at the Equinix Ashburn Campus. This dedicated facility provides a platform for Equinix to work with companies that are developing innovative technologies, helping customers see and experience these solutions in action. “This kind of collaboration is a powerful way to demonstrate our technology in real-world scenarios,” said Josh Claman, CEO of Accelsius. “The key thing we’re finding with all the customers we’re talking to is making it tangible to them—helping them see it and visualize how it’s going to work for them. It’s...